Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.96 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.96 |
| ▸ | FNTA | P49354 | 4/20 | 0.60 |
| ▸ | FNTB | P49356 | 4/20 | 0.60 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28486071 | 1.00 | ALDH1A1 (0.96) | ALDH1A1ALOX15FNTAFNTBPGGT1B | |
| SCHEMBL11404533 | 1.00 | ALDH1A1 (0.96) | ALDH1A1ALOX15FNTAFNTBPGGT1B | |
| SCHEMBL11410939 | 1.00 | ALDH1A1 (0.96) | ALDH1A1ALOX15FNTAFNTBPGGT1B | |
| SCHEMBL806825 | 1.00 | ALDH1A1 (0.96) | ALDH1A1ALOX15FNTAFNTBPGGT1B | |
| SCHEMBL806928 | 1.00 | ALDH1A1 (0.96) | ALDH1A1ALOX15FNTAFNTBPGGT1B | |
| SCHEMBL1301763 | 1.00 | ALDH1A1 (0.96) | ALDH1A1ALOX15FNTAFNTBPGGT1B | |
| SCHEMBL806725 | 1.00 | ALDH1A1 (0.96) | ALDH1A1ALOX15FNTAFNTBPGGT1B | |
| SCHEMBL11404530 | 1.00 | ALDH1A1 (0.96) | ALDH1A1ALOX15FNTAFNTBPGGT1B | |
| SCHEMBL133908 | 1.00 | ALDH1A1 (0.96) | ALDH1A1ALOX15FNTAFNTBPGGT1B | |
| SCHEMBL806690 | 1.00 | ALDH1A1 (0.96) | ALDH1A1ALOX15FNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110133140-B | Component identification and bacteriostatic activity research of volatile oil of aerial parts of dictamnus dasycarpus | 吉林化工学院 | 2022-07-12 | — | — | CN | claimed |
| EP-1088333-A4 | COMPOSITIONS AND METHODS FOR INHIBITING BONE RESORPTION | MERCK & CO INC (US) | 2005-08-10 | — | — | EP | claimed |
| US-6699850-B2 | ORAL FORMULATION OF A COMBINATION OF NITROGEN-CONTAINING BISPHOSPHONATE OR ITS SALT AND AN ISOPRENOID COMPOUND FOR INHIBITING BONE RESOPRTION IN A MAMMAL WHILE COUNTERACTING THE OCCURRENCE OF ADVERSE GASTROINTESTINAL EFFECT | MERCK & CO., INC. | 2004-03-02 | — | — | US | claimed |
| EP-1089731-A4 | COMPOSITIONS AND METHODS FOR TREATING ELEVATED BLOOD CHOLESTEROL | MERCK & CO INC (US) | 2003-06-18 | — | — | EP | claimed |
| US-20020082244-A1 | Compositions and methods for inhibiting bone resorption | MERCK & CO., INC. | 2002-06-27 | — | — | US | claimed |
| EP-1089731-A1 | COMPOSITIONS AND METHODS FOR TREATING ELEVATED BLOOD CHOLESTEROL | Merck & Co., Inc. (US) | 2001-04-11 | — | — | EP | claimed |
| EP-1088333-A1 | COMPOSITIONS AND METHODS FOR INHIBITING BONE RESORPTION | Merck & Co., Inc. (US) | 2001-04-04 | — | — | EP | claimed |
| WO-1999067809-A9 | COMPOSITIONS AND METHODS FOR INHIBITING BONE RESORPTION | MERCK & CO INC (US) | 2001-03-22 | — | — | WO | claimed |
| WO-1999066929-A1 | COMPOSITIONS AND METHODS FOR TREATING ELEVATED BLOOD CHOLESTEROL | MERCK & CO., INC. (US) | 1999-12-29 | — | — | WO | claimed |
| WO-1999067809-A1 | COMPOSITIONS AND METHODS FOR INHIBITING BONE RESORPTION | MERCK & CO., INC. (US) | 1999-12-29 | — | — | WO | claimed |
| EP-4590262-A2 | ORAL CARE COMPOSITIONS COMPRISING GERANYLGERANIOL AND METHODS OF USE THEREOF | American River Nutrition, LLC (US) | 2025-07-30 | — | — | EP | disclosed |
| CN-120053668-A | Topical preparation containing lipid formed by non-lamellar liquid crystal | 法纳克斯株式会社 | 2025-05-30 | — | — | CN | disclosed |
| CN-112770778-B | Topical preparation containing lipid formed by non-lamellar liquid crystal | 法纳克斯株式会社 | 2025-03-04 | — | — | CN | disclosed |
| US-20240197589-A1 | ORAL CARE COMPOSITIONS COMPRISING GERANYLGERANIOL AND METHODS OF USE THEREOF | AMERICAN RIVER NUTRITION, LLC (US) | 2024-06-20 | — | — | US | disclosed |
| WO-2024064959-A2 | ORAL CARE COMPOSITIONS COMPRISING GERANYLGERANIOL AND METHODS OF USE THEREOF | AMERICAN RIVER NUTRITION, LLC (US) | 2024-03-28 | — | — | WO | disclosed |
| EP-1089731-A1 | COMPOSITIONS AND METHODS FOR TREATING ELEVATED BLOOD CHOLESTEROL | Merck & Co., Inc. (US) | 2001-04-11 | — | — | EP | disclosed |
| EP-1088333-A1 | COMPOSITIONS AND METHODS FOR INHIBITING BONE RESORPTION | Merck & Co., Inc. (US) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999067809-A9 | COMPOSITIONS AND METHODS FOR INHIBITING BONE RESORPTION | MERCK & CO INC (US) | 2001-03-22 | — | — | WO | disclosed |
| WO-1999066929-A1 | COMPOSITIONS AND METHODS FOR TREATING ELEVATED BLOOD CHOLESTEROL | MERCK & CO., INC. (US) | 1999-12-29 | — | — | WO | disclosed |
| WO-1999067809-A1 | COMPOSITIONS AND METHODS FOR INHIBITING BONE RESORPTION | MERCK & CO., INC. (US) | 1999-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240197589-A1 | ORAL CARE COMPOSITIONS COMPRISING GERANYLGERANIOL AND METHODS OF USE THEREOF | GGPS1, GLA, GMPS | ALDH1A1 4482/4885ALOX15 1585/4885FNTA 95/4885 |
| US-20020082244-A1 | Compositions and methods for inhibiting bone resorption | SOST, PTEN, ALPI | ALDH1A1 4552/4885ALOX15 441/4885FNTA 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.